[Sensitivity and resistance to antimicrobial agents ESBL-producing and not producing ESBL strains of E. coli in patients with urinary tract infection.]

[Sensitivity and resistance to antimicrobial agents ESBL-producing and not producing ESBL strains of E. coli in patients with urinary tract infection.]

Klin Lab Diagn. 2019;64(2):104-110

Authors: Dimitrova NI, Gasretova TD, Alutina EL, Kharseeva GG

Abstract
As a result of the conducted researches it is shown that 44.1% of urinary tract infections (UTIS) caused by E. coli are accounted for by producers of beta-lactamase of the extended spectrum of action (ESBL). Associated resistance to fluoroquinolones and co-trimoxazole was found in 93.3% of BLRS-producing E. coli strains. All studied strains regardless of ESBL production were sensitive to imipenem, the majority showed sensitivity to ertapenem, gentamicin and resistance to doxycycline. Not producing ESBL strains of E. coli were sensitive to fosfomycin. Comparison of data obtained during testing of isolated cultures on ESBL, study of their sensitivity and resistance to beta-lactams (amoxicillin/clavulanate, ceftazidime, ceftriaxone, cefotaxime, imipenem) indicates the need to test isolates for AmpC products. To this end, during the screening test for ESBL and the method of «double disks», along with cephalosporins of III generation, it is necessary to use a phenotypic test for sensitivity to cefepime. The use of test results of E. coli isolates isolated from patients with UTIS for the production of ESBL, ampC enzymes, carbapenemase and sensitivity to AMP will improve the effectiveness of antimicrobial therapy and will help to curb the formation and spread of antimicrobial-resistan strains.

PMID: 30917252 [PubMed - in process]